Sun Pharma's Taro Unit Recalls 17,664 Units of Ciclopirox Shampoo in US Due to Manufacturing Quality Issues
Key Insights
Taro Pharmaceutical Industries, a wholly-owned subsidiary of Sun Pharma, initiated a Class II nationwide recall of 17,664 units of Ciclopirox Shampoo (search) on December 9, 2024.
The antifungal medication used to treat seborrheic dermatitis (search) was recalled due to failed impurity and degradation specifications identified during manufacturing quality control.
The USFDA (search) classified this as a Class II recall, indicating potential for temporary or medically reversible health consequences with minimal likelihood of serious adverse outcomes.
Taro Pharmaceutical Industries, a wholly-owned subsidiary of Sun Pharmaceutical Industries, has initiated a nationwide recall of 17,664 units of Ciclopirox Shampoo (search) in the United States due to manufacturing quality control failures. The US Food and Drug Administration (USFDA (search)) announced the Class II recall in its latest Enforcement Report, citing "Failed Impurity/Degradation specifications" as the reason for the action.
Product and Indication Details
Ciclopirox Shampoo (search) is an antifungal medication specifically indicated for the treatment of seborrheic dermatitis (search), a common dermatological condition characterized by dry, flaky, and itchy skin. The recalled product was manufactured at Taro's Hawthorne-based facility and distributed nationwide before quality control issues were identified.
Regulatory Classification and Risk Assessment
The USFDA (search) classified this action as a Class II recall, which is initiated when the use of or exposure to a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. The recall was formally initiated on December 9, 2024, affecting the specific lot that failed to meet established impurity and degradation specifications.
Corporate Background and Market Context
Sun Pharmaceutical Industries completed its merger with Taro Pharmaceutical Industries in a transaction valued at $347.73 million in 2023, making Taro a private company wholly owned by Sun Pharma. Sun Pharma has maintained majority shareholder status in Taro since 2010, with the subsidiary primarily focused on dermatology products, producing a comprehensive range of both prescription and over-the-counter medications.
This recall occurs within the broader context of Indian pharmaceutical companies' significant presence in the US market. According to the source data, Indian companies supplied four out of ten prescriptions filled in the United States in 2022, representing a substantial proportion of the American drug supply chain.
Manufacturing Quality Implications
The failed impurity and degradation specifications that triggered this recall underscore the critical importance of maintaining stringent quality control standards in pharmaceutical manufacturing. Such specifications are designed to ensure that active pharmaceutical ingredients maintain their potency and safety profile throughout the product's shelf life, while preventing the accumulation of potentially harmful degradation products or impurities that could compromise patient safety or therapeutic efficacy.